Michigan Medicine

Dr. Gary Monash Joins Arizona Digestive Health in Tucson

Retrieved on: 
金曜日, 5月 24, 2024
IBD, Patient, EMD, University of Michigan, Health, University, Suite, Enteric nervous system, Michigan State University, Michigan Medicine, Inflammatory bowel disease, GI, Physiology, Nursing

Tucson, AZ, May 24, 2024 (GLOBE NEWSWIRE) -- Arizona Digestive Health is honored to welcome Dr. Gary Monash, a physician experienced in treating all gastrointestinal diseases, with special interest in Inflammatory Bowel Disease (IBD) and Esophageal Motility Disorders (EMD).

Key Points: 
  • Tucson, AZ, May 24, 2024 (GLOBE NEWSWIRE) -- Arizona Digestive Health is honored to welcome Dr. Gary Monash, a physician experienced in treating all gastrointestinal diseases, with special interest in Inflammatory Bowel Disease (IBD) and Esophageal Motility Disorders (EMD).
  • Dr. Monash is a seasoned, board-certified gastroenterologist who received his graduate degree from University of Michigan and his medical degree from Michigan State University.
  • “I have always enjoyed the physiology of the GI tract and contiguous organs,” says Dr. Monash.
  • ADH-Tucson is at 7490 N. Oracle Road, Suite 210, Tucson, AZ , and is open Monday through Friday, 9am to 4:30pm (2:30pm on Fridays).

New Data Validating the First AI-Based Biomarker to Stratify Risk of Metastasis in Radical Prostatectomy Patients with Biochemical Recurrence

Retrieved on: 
月曜日, 5月 6, 2024
Research, Other Health, General Health, Oncology, Biometrics, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, Prostate cancer, Disease, MMAI, Michigan Medicine, BCR, Prostate, Patient, Metastasis, Risk

ArteraAI , the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the validation of its first multimodal artificial intelligence (MMAI) digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence (BCR).

Key Points: 
  • ArteraAI , the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the validation of its first multimodal artificial intelligence (MMAI) digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence (BCR).
  • Researchers successfully trained and validated the model for patients who experience BCR after radical prostatectomy surgery, which is strongly associated with the risk of the disease spreading.
  • The data was presented by Dr. Todd Morgan from Michigan Medicine as an oral presentation at the 2024 AUA Annual Meeting, on Sunday, May 5, 2024.
  • A radical prostatectomy is the removal of the prostate in a patient with prostate cancer and has served as a primary treatment for this disease for many years.

Urology Care Foundation Announces 2024 Research Awards of Distinction

Retrieved on: 
木曜日, 4月 4, 2024
Western University, Research, American Urological Association, Xenobiotic, Translational research, Postdoctoral researcher, Prostate cancer, Environment, Lawson Health Research Institute, Immunology, Committee, Gut microbiota, University, Macrophage, Doctor of Philosophy, Role, Publication, Pediatrics, University of California, Pediatric urology, Division, FACS, Radiation therapy, Society, Michigan Medicine, Nursing

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.
  • "We are optimistic about the future of urologic research with the selection of the recipients of this year’s Urology Care Foundation Research Awards,” said Harris M. Nagler, MD, Urology Care Foundation President.
  • “We are thrilled with the Urology Care Foundation Research Awards of Distinction awardees this year,” said Steven Kaplan, MD, Chair of the AUA’s Research Council.
  • The awardees will be celebrated at the Urology Care Foundation Research Honors Program held at the AUA Annual Meeting in May 2024.

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 4月 1, 2024
Research, Glucose, Health, Congress, Obesity, Human, Drug discovery, Exercise, Glycated hemoglobin, DMR, ADAS, Partnership, Insulin, IDA, Patient, Weight loss, Michigan Medicine, Diabetes, Public expenditure, IDE, University, IPO, Tropism, Peptide, Transgene, Insulin resistance, Animal, NUB, Type 2 diabetes, Pancreas, Investigational New Drug, Therapy, Food, Marketing, FDA, Engineering, Annual general meeting, Pharmaceutical industry

BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today reported its fourth quarter and full year 2023 financial results and provided a business update.

Key Points: 
  • “In addition, we expect to complete enrollment of our pivotal Revitalize-1 study and are excited to report topline data in the fourth quarter of 2024.
  • The Company expects to complete enrollment in the first half of 2024 and report topline data in the fourth quarter of 2024.
  • In December 2023, Fractyl presented preclinical findings in an oral presentation at the World Congress of Insulin Resistance Diabetes and Cardiovascular Disease 2023 Annual Meeting.
  • Cash Position: As of December 31, 2023, Fractyl had approximately $33.2 million in cash and cash equivalents.

Pulsenmore is expanding the application of its home ultrasound solution for pregnant women: a clinical trial with Michigan Medicine will focus on the remote assessment of the fetal biophysical profile

Retrieved on: 
水曜日, 3月 13, 2024
Principal, Pregnancy, Sheba Medical Center, Growth, COVID-19, Patient, Prenatal care, Michigan Medicine, Transport, University, Telehealth, MD, Trial of the century, Gynaecology, Safety, BPP, Marketing, Movement, Obstetrics, Medical imaging

The study will examine the ability to conduct a remote biophysical profile (BPP) test, by using the Pulsenmore home ultrasound with the guidance of a remote clinician, potentially reducing the clinical burden.

Key Points: 
  • The study will examine the ability to conduct a remote biophysical profile (BPP) test, by using the Pulsenmore home ultrasound with the guidance of a remote clinician, potentially reducing the clinical burden.
  • The Pulsenmore prenatal home ultrasound, empowers pregnant women to connect their personal smartphones to a dedicated device and application, allowing them to perform ultrasound imaging scans from the comfort of their homes.
  • These scans are seamlessly transmitted to the hospital for evaluation, focusing on essential fetal vitality parameters.
  • The company continues to expand its operations by growing its' distribution and collaborations with health organizations in key markets.

Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Retrieved on: 
火曜日, 2月 27, 2024
Cardiorenal syndrome, Division, Inflammation, FDA, Food, SCD, Emeritus, Manuscript, Hospital, Heart failure, European Journal, University, SeaStar, Internal medicine, Glucocorticoid, Acute kidney injury, Michigan Medicine, Drug, Monocyte, FACC, Acute respiratory distress syndrome, LVAD, Mortality, Heart, Pharmaceutical industry

DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces publication of a manuscript discussing the role of chronic dysregulated systemic inflammation in heart failure and the potential application of the adult Selective Cytopheretic Device, part of the Quelimmune™ product family, in enabling previously ineligible patients with severe disease to receive a left ventricular assist device (LVAD) or heart transplant in the peer-reviewed European Journal of Heart Failure February 2024, Pitt, B., Iyer, S.P.N. and Humes, H.D. (2024), Eur J Heart Fail. https://doi.org/10.1002/ejhf.3177.

Key Points: 
  • The manuscript, titled “New Opportunity for Targeting Systemic Inflammation in Patients with Heart Failure through Leukocyte Immunomodulation” cites increasing evidence of the role of chronic systemic inflammation in patients with heart failure and discusses the Adult SCD’s potential to improve hypertensive heart failure and mortality following hospitalization for acute or worsening heart failure.
  • Following treatment with the Adult SCD, this patient was effectively bridged to LVAD three days after discontinuing treatment and was subsequently discharged without further complications.
  • “Prior attempts targeting singular proinflammatory factors as well as systemic immunosuppression with glucocorticoids in patients with acute heart failure have yielded unclear results, raising the need to identify new strategies.
  • “While our manuscript discusses a positive outcome in one patient following treatment for six hours daily over six consecutive days, the results suggest that more study with Adult SCD is warranted for patients with heart failure and hyperinflammation.”

BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity

Retrieved on: 
水曜日, 12月 6, 2023
NAFLD, Risk, NASH, MOA, Non-alcoholic fatty liver disease, Small RNA, Michigan Medicine, Diabetes, Bullfrog, Obesity, University, Fatty liver disease, University of Michigan, DSM-IV codes, Artificial intelligence, Machine learning, SPTBN1, Medical device

GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the launch of a preclinical study to evaluate the efficacy of its drug candidate BF-114 in obesity. The study, which will be conducted in collaboration with Randy Seeley, Ph.D., the Henry King Ransom Endowed Professor of Surgery at Michigan Medicine, the academic medical center of University of Michigan, and Director of the Michigan Nutrition Obesity Research Center, is designed to evaluate the ability of BF-114 to modulate obesity in an established animal model and to elucidate the mechanism of action (MOA). The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.

Key Points: 
  • The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.
  • Obesity affects over 40% of the US population and is associated with increased risk of heart disease and diabetes.
  • Medical care costs for obesity-related health problems were estimated to be in excess of $170 billion in 2019.
  • “The market for obesity drugs is projected to exceed $77 billion by 2030 , and pharmaceutical companies around the world have recognized the importance of targeting multiple pathways to treat this condition,” said Vin Singh, CEO of BullFrog AI.

Fractyl Health Expands Landmark Academic-Industry Collaboration to Study Mechanisms Underlying GLP-1-Based Pancreatic Gene Therapy for Type 2 Diabetes and Obesity

Retrieved on: 
木曜日, 11月 16, 2023
Research, DSM-IV codes, Conditional sentence, Entrepreneurship, University, T2D, Pancreas, Type 2 diabetes, Obesity, Therapy, Partnership, Michigan Medicine, Weight loss, Pharmaceutical industry

The new research, to be led by Professor Randy Seeley, Ph.D., of Michigan Medicine, is intended to explore the mechanistic rationale underlying the use of local pancreatic gene therapy to produce targeted treatment options that address, and hopefully remit, metabolic diseases.

Key Points: 
  • The new research, to be led by Professor Randy Seeley, Ph.D., of Michigan Medicine, is intended to explore the mechanistic rationale underlying the use of local pancreatic gene therapy to produce targeted treatment options that address, and hopefully remit, metabolic diseases.
  • “T2D and obesity are two of society’s most vexing chronic diseases.
  • We now have much better tools in the toolbox, but all rely on chronic therapy to achieve their benefits.
  • “We are excited to deepen our scientific collaboration with Dr. Seeley to explore the metabolic mechanisms underpinning a one-time gene therapy in the pancreas.”

As part of seven outputs being tested and evaluated, ECA announces Pioneering Pilots to Address Tech Challenges as part of World Early Childhood Development (WED) Movement

Retrieved on: 
月曜日, 11月 27, 2023
Team, Assistant, City University, Policy, Screen time, ECA, Movement, WED, Science, Humanity, Aircraft, University of Dubai, Caregiver, Cognitive development, Social media, Abu Dhabi Investment Office, Emirate, City, NYU, Digital technology, University, BWG, Learning, Parent, Hearing, Abbreviation, GCC, ECD, Michigan Medicine, Government, Education, US Global Development Lab, Toy, Child

ABU DHABI, UAE, Nov. 27, 2023 /PRNewswire/ --  Abu Dhabi Early Childhood Authority (ECA) announced the roll out of two key outputs as part of the World Early Childhood Development (WED) Movement.

Key Points: 
  • ABU DHABI, UAE, Nov. 27, 2023 /PRNewswire/ --  Abu Dhabi Early Childhood Authority (ECA) announced the roll out of two key outputs as part of the World Early Childhood Development (WED) Movement.
  • The progress of the pilots will be unveiled at the bi-annual WED Forum and an inaugural Tech Humanity for Children Symposium in 2024.
  • World Early Childhood Development (WED) Movement is a pioneering initiative that unitesglobal and local experts, partners, and innovators to address global Early Childhood Development (ECD) challenges.
  • WED Movement collaborates with key partners and government entities to improve Early Childhood Development (ECD) services and outcomes, through the Abu Dhabi Early Childhood Development Strategy 2035.

As part of seven outputs being tested and evaluated, ECA announces Pioneering Pilots to Address Tech Challenges as part of World Early Childhood Development (WED) Movement

Retrieved on: 
月曜日, 11月 27, 2023
Team, Assistant, City University, Policy, Screen time, ECA, Movement, WED, Science, Humanity, Aircraft, University of Dubai, Caregiver, Cognitive development, Social media, Abu Dhabi Investment Office, Emirate, City, NYU, Digital technology, University, BWG, Learning, Parent, Hearing, Abbreviation, GCC, ECD, Michigan Medicine, Government, Education, US Global Development Lab, Toy, Child

ABU DHABI, UAE, Nov. 27, 2023 /PRNewswire/ --  Abu Dhabi Early Childhood Authority (ECA) announced the roll out of two key outputs as part of the World Early Childhood Development (WED) Movement.

Key Points: 
  • ABU DHABI, UAE, Nov. 27, 2023 /PRNewswire/ --  Abu Dhabi Early Childhood Authority (ECA) announced the roll out of two key outputs as part of the World Early Childhood Development (WED) Movement.
  • The progress of the pilots will be unveiled at the bi-annual WED Forum and an inaugural Tech Humanity for Children Symposium in 2024.
  • World Early Childhood Development (WED) Movement is a pioneering initiative that unitesglobal and local experts, partners, and innovators to address global Early Childhood Development (ECD) challenges.
  • WED Movement collaborates with key partners and government entities to improve Early Childhood Development (ECD) services and outcomes, through the Abu Dhabi Early Childhood Development Strategy 2035.